Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress.
- Author:
Shiping CAO
1
;
Peng WANG
;
Kai CUI
;
Li ZHANG
;
Yuqing HOU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Atorvastatin Calcium; Contrast Media; adverse effects; Coronary Angiography; adverse effects; Female; Heptanoic Acids; administration & dosage; pharmacology; therapeutic use; Humans; Kidney Diseases; chemically induced; prevention & control; Male; Middle Aged; Oxidative Stress; drug effects; Pyrroles; administration & dosage; pharmacology; therapeutic use
- From: Journal of Southern Medical University 2012;32(11):1600-1602
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of atorvastatin in preventing contrast agent-induced nephropathy (CIN) in patients undergoing coronary angiography and explore the mechanism.
METHODSA total of 180 patients undergoing coronary angiography or percutaneous coronary interventions (PCI) were randomized into regular dose and high dose atorvastatin groups (n=90). Serum creatinine (Scr), glomerular filtration rate (GFR), cystatin, peripheral blood levels of myeloperoxidase (MPO), malondialdehyde (MDA), and superoxide dismutase (SOD) before and after the procedure were compared between the two groups.
RESULTSThe incidence of CIN was significantly lower in high-dose atorvastatin group than in the regular dose group. At 48-72 h after the surgery, serum Scr and cystatin levels were significantly lower and eGFR was significantly higher in the high-dose group. At 24 h after the surgery, MPO and MDA levels were significantly lower, and SOD activity was significantly higher in high-dose group than in the regular dose group.
CONCLUSIONHigh-dose atorvastatin used before angiography is more effective than the regular dose in attenuating contrast agent-induced renal dysfunction, and its mechanism is related with the inhibition of oxidative stress.
